Gamma-aminobutyric acid type A receptor subunit alpha 6 (GABRA6)

The Gamma-aminobutyric acid type A receptor subunit alpha 6 (GABRA6) is a key component of specific GABA_A receptor subtypes that are predominantly expressed in the cerebellar granule cells and the trigeminal ganglia [2, 3, 5]. These receptors play a specialized role in mediating both phasic and tonic inhibitory neurotransmission, which is essential for processes such as sensorimotor gating and the modulation of trigeminal pain signaling [1, 2, 3]. A defining pharmacological feature of alpha 6-containing receptors is their insensitivity to classical benzodiazepines like diazepam, while remaining sensitive to selective modulators such as certain pyrazoloquinolinones and the antagonist furosemide [2, 17]. Research has identified these receptors as promising therapeutic targets for a variety of conditions, including schizophrenia, migraine, and trigeminal neuralgia, where they help restore inhibitory balance [1, 2, 6]. Genetic studies have further linked variations in the GABRA6 gene to epilepsy, alcohol use disorders, and stress-related phenotypes, underscoring its importance in maintaining neurological stability [9, 12].

Other names

GABA_A receptor alpha 6 subunitGABAAR subunit alpha-6Gamma-aminobutyric acid receptor subunit alpha-6alpha6GABAARGABRA6

Positive allosteric modulation of the GABA_A receptor complex, specifically at the alpha-beta or alpha-gamma interface, which increases the frequency or duration of chloride channel opening in response to GABA [1, 15, 17]. This leads to an increased influx of chloride ions, causing membrane hyperpolarization and a reduction in neuronal excitability [7, 15].